• Safety & Recalls
  • Regulatory Updates
  • Drug Coverage
  • COPD
  • Cardiovascular
  • Obstetrics-Gynecology & Women's Health
  • Ophthalmology
  • Clinical Pharmacology
  • Pediatrics
  • Urology
  • Pharmacy
  • Idiopathic Pulmonary Fibrosis
  • Diabetes and Endocrinology
  • Allergy, Immunology, and ENT
  • Musculoskeletal/Rheumatology
  • Respiratory
  • Psychiatry and Behavioral Health
  • Dermatology
  • Oncology

Pipeline Preview


Recent FDA action (through April 2012) related to, Dihydroergotamine, Levadex inhalation aerosol, droxidopa, Northera, Amitriptyline 4% ketamine 2% cream, AmiKet, Afilbercept, ZALTRAP, Nav rAAV8 vector, Carbamazepine, Carbatrol, Vancomycin hydrochloride, Vancocin, Irbesartan, irbesartan-hydrochloriderothiazide, Avapro, Avalide, Fluvastatin, Lescol

Complete response

Fast-track designation

Priority review

First-time generic approvals

Carbamazepine extended-release capsules in 100-mg, 200-mg, and 300-mg strengths (equiv to Carbatrol)

Vancomycin hydrochloride, USP Capsules (equiv to Vancocin)

Irbesartan and irbesartan-hydrochlorothiazide tablets (equiv to Avapro and Avalide tablets)

Fluvastatin capules USP, 20-mg and 40-mg strengths (equiv to Lescol)

Related Content
© 2024 MJH Life Sciences

All rights reserved.